ZyVersa Therapeutics, Inc.
Navigate ZyVersa Therapeutics, Inc.
Home
About
About
Our Vision/Mission
Management Team
CEOCFO Magazine Interview With CEO
Board of Directors
Scientific Advisory Board: Inflammatory Diseases
Scientific Advisory Board: Renal Disease
Inflammasomes
Inflammasomes
IC 100: ASC Inhibitor
IC 100: MOA Video
IC 100 Infographic, Mechanism of Action
ASC Biomarker
Inflammasome Publications
White Paper: Inflammasomes, a Promising Therapeutic and Diagnostic Target
Renal Lipids
Renal Lipids
VAR 200, Cholesterol Efflux Mediator, 2HPβCD
Cyclodextrin Publications
Renal Disease Publications
Pipeline
Pipeline
Collaboration
About FSGS
About Alport Syndrome
About Lupus nephritis
About Diabetic Kidney Disease
About Multiple Sclerosis
About NASH
Careers
News Center
Corporate News Releases
Corporate Presentations
Media Resources
Corporate Media Contact
ZyVersa Featured Article, Business Worldwide Magazine
Contact
Home
News Center
Corporate News Releases
Corporate News Releases
Jan 30, 2020 • 7:08 AM EST
ZyVersa Therapeutics Featured in Business Worldwide Magazine's Winter Edition as One of the 20 Most Innovative Companies to Watch
Jan 20, 2020 • 7:08 AM EST
ZyVersa Therapeutics Releases Video Demonstrating How Inflammasomes Stimulate and Perpetuate Inflammation, and How a Novel Inflammasome Inhibitor, IC 100, Has Potential to Control Chronic Damaging Inflammation Associated with Inflammatory Diseases
Jan 6, 2020 • 7:08 AM EST
ZyVersa Therapeutics' CEO, Stephen C. Glover to Attend the 38th Annual J.P. Morgan Healthcare Conference 2020
Dec 18, 2019 • 4:00 PM EST
Business Worldwide Magazine Names ZyVersa Therapeutics in Twenty Most Innovative Companies to Watch
Nov 13, 2019 • 7:08 AM EST
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Stifel 2019 Healthcare Conference
Oct 28, 2019 • 7:08 AM EDT
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Inaugural Inflammasome Therapeutics Summit on October 30th, 2019
Oct 14, 2019 • 7:08 AM EDT
ZyVersa Therapeutics' Viewpoint on "Why Kidney Indications Are Coming into Sharp Focus" Reported in BIOCENTURY Innovations' Article
Sep 25, 2019 • 6:55 AM EDT
Interview with ZyVersa Therapeutics' CEO, Stephen C. Glover, Published in CEOCFO Magazine
Sep 19, 2019 • 7:03 AM EDT
ZyVersa Therapeutics Unveils a White Paper Fostering Education About Inflammasomes and Their Potential as a Promising Therapeutic and Diagnostic Target for Inflammatory Diseases
Sep 12, 2019 • 7:08 AM EDT
ZyVersa Therapeutics' Perspectives on Inflammasomes Reported in BIOCENTURY Innovations Article
